MARKET

ZGNX

ZGNX

Zogenix
NASDAQ

Real-time Quotes | Nasdaq Last Sale

24.81
+0.05
+0.20%
After Hours: 24.00 -0.81 -3.26% 19:21 08/13 EDT
OPEN
24.61
PREV CLOSE
24.76
HIGH
25.20
LOW
24.52
VOLUME
564.59K
TURNOVER
--
52 WEEK HIGH
57.22
52 WEEK LOW
16.65
MARKET CAP
1.38B
P/E (TTM)
-2.6097
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 12 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ZGNX stock price target is 48.36 with a high estimate of 69.00 and a low estimate of 25.00.

EPS

ZGNX News

More
Zogenix (ZGNX) Reports Q2 Loss, Misses Revenue Estimates
Zogenix (ZGNX) delivered earnings and revenue surprises of 5.88% and -6.18%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 08/06 02:15
Zogenix EPS beats by $0.04, beats on revenue
Zogenix (NASDAQ:ZGNX): Q2 GAAP EPS of -$0.96 beats by $0.04. Revenue of $1.03M (-3.7% Y/Y) beats by $0.48M. Press Release
seekingalpha · 08/06 01:13
Zogenix Provides Corporate Update and Reports Second Quarter 2020 Financial Results
* FINTEPLA® (fenfluramine) in Dravet syndrome is now FDA approved and commercially launched in the U.S. * More than 230 prescribers have already completed FINTEPLA REMS enrollment and certification * FDA meeting scheduled in September to discuss pla
GlobeNewswire · 08/05 20:01
Zogenix to Release Second Quarter 2020 Financial Results and Host Conference Call and Webcast on August 5
EMERYVILLE, Calif., July 29, 2020 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it will report its financial results for the three and six months ended June 30, 2020, a
GlobeNewswire · 07/29 12:00
Earnings Preview: Zogenix (ZGNX) Q2 Earnings Expected to Decline
Zogenix (ZGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 07/28 16:33
Zogenix: A Critical Launch
Seeking Alpha - Article · 07/06 11:58
Zogenix's Long-Awaited Drug Approved With a Warning
Seizure medication must have black box warning due to safety issues Continue reading...
GuruFocus.com · 07/05 19:45
Zogenix (ZGNX) in Focus: Stock Moves 7.6% Higher
Zacks · 07/02 13:53

Industry

Biotechnology & Medical Research
+0.99%
Pharmaceuticals & Medical Research
-0.06%

Hot Stocks

Symbol
Price
%Change

About ZGNX

Zogenix, Inc. is a pharmaceutical company engaged in developing and commercializing central nervous system (CNS) therapies that address specific clinical needs for people living with orphan and other CNS disorders. Its primary area of therapeutic focus is epilepsy and related seizure disorders. Its lead product candidate, ZX008, is a low-dose fenfluramine for the treatment of seizures associated with Dravet syndrome. ZX008 has received orphan drug designation in the United States and European Union (EU), for the treatment of Dravet syndrome. The Company has an additional product candidate, Relday (risperidone once-monthly long-acting injectable) for the treatment of schizophrenia. Relday is a long-acting injectable formulation of risperidone. Risperidone is used to treat the symptoms of schizophrenia and bipolar disorder in adults and teenagers 13 years of age and older. It has completed the Phase I program for Relday.
More

Webull offers kinds of Zogenix, Inc. stock information, including NASDAQ:ZGNX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ZGNX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ZGNX stock methods without spending real money on the virtual paper trading platform.